Provided are a polymer medicament for treating hyperkalemia, and a preparation method thereof. Specifically, a polymer is provided, and the polymer includes repeating units obtained by polymerizing a monomer and a crosslinking agent. A molar ratio of the monomer to the crosslinking reagent ranges from 1:0.02 to 1:0.20. The monomer includes an acidic group and a pKa-reducing group next to the acidic group. The acidic group is selected from the group consisting of sulfonic acid group (—SO.sub.3—), sulfuric acid group (—OSO.sub.3—), carboxylic group (—CO.sub.2—), phosphonic acid group (—OPO.sub.3.sup.2—), phosphate group (—OPO.sub.3.sup.2—), and sulfamic acid group (—NHSO.sub.3—). The pKa-reducing group is selected from the group consisting of nitro, cyano, carbonyl, trifluoromethyl, and halogen atoms. The crosslinking agent has three or four reaction sites. The polymer can be used to treat hyperkalemia.

Methods for treatment of people afflicted with COVID-19 are described. The methods include administration of azoximer bromide to people afflicted with COVID-19. Methods of prophylaxis against COVID-19 by administering azoximer bromide are also described herein. The methods include administration of azoximer bromide to healthy people not afflicted with COVID-19. Azoximer bromide may be administered intravenously, as a pill, nasal spray, and/or suppository, with each treatment dose being designed to complement the mode of administration. Azoximer bromide may be administered for treating COVID-19 as part of a complex therapy including at least one of a vitamin, mineral, antibiotic, antiviral, immunosuppressant, hydroxychloroquine, and anti-coagulant.

Methods for treatment of people afflicted with COVID-19 are described. The methods include administration of azoximer bromide to people afflicted with COVID-19. Methods of prophylaxis against COVID-19 by administering azoximer bromide are also described herein. The methods include administration of azoximer bromide to healthy people not afflicted with COVID-19. Azoximer bromide may be administered intravenously, as a pill, nasal spray, and/or suppository, with each treatment dose being designed to complement the mode of administration. Azoximer bromide may be administered for treating COVID-19 as part of a complex therapy including at least one of a vitamin, mineral, antibiotic, antiviral, immunosuppressant, hydroxychloroquine, and anti-coagulant.

Monomers and copolymers are provided that both target antigen presenting cells (APCs) and activate toll-like receptor (TLR) on the APCs. In some embodiments, compositions and methods involve a polymer that targets the mannose receptor on APCs, in addition to activating a TLR. These can then be conjugated to protein antigens to efficiently target antigens to DCs and simultaneously induce the up-regulation of co-stimulatory molecules that are essential for effective T cell activation. This copolymer is a more efficient activator of DCs, as measured by the surface expression of co-stimulatory molecules and the release of proinflammatory cytokines, than the monomeric form the TLR agonist used in the polymer formulation. Aspects of the disclosure relate to novel compounds, methods, and compositions for treating diseases using the compounds, copolymers, and compositions described herein.

Monomers and copolymers are provided that both target antigen presenting cells (APCs) and activate toll-like receptor (TLR) on the APCs. In some embodiments, compositions and methods involve a polymer that targets the mannose receptor on APCs, in addition to activating a TLR. These can then be conjugated to protein antigens to efficiently target antigens to DCs and simultaneously induce the up-regulation of co-stimulatory molecules that are essential for effective T cell activation. This copolymer is a more efficient activator of DCs, as measured by the surface expression of co-stimulatory molecules and the release of proinflammatory cytokines, than the monomeric form the TLR agonist used in the polymer formulation. Aspects of the disclosure relate to novel compounds, methods, and compositions for treating diseases using the compounds, copolymers, and compositions described herein.

The disclosure provides polymers and compositions thereof, as well as methods for preparing such polymers and compositions. Also provided is a method of using the polymers or compositions thereof for binding uric acid or precursor thereof, and/or for treating hyperuricemia, gout, and/or diseases caused by hyperuricemia.

The disclosure provides polymers and compositions thereof, as well as methods for preparing such polymers and compositions. Also provided is a method of using the polymers or compositions thereof for binding uric acid or precursor thereof, and/or for treating hyperuricemia, gout, and/or diseases caused by hyperuricemia.

There is provided a β-peptido sugar-copolymer having the structure of formula (I) as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of the same. There is provided a process to make the β-peptido sugar-copolymer as defined herein. There are further provided medical applications of the β-peptido sugar-copolymer as defined herein. In a preferred embodiment, a block-like copolymer poly(amido-D-glucose)-block-poly-β-(L)-homolysine (PDGu-b-PBLK) synthesized via anionic ring-opening polymerization (ROP) demonstrates an antimicrobial efficacy, an enhanced selectivity towards different bacteria, biocompatibility vs. mammalian cells and spontaneous assembly.

There is provided a β-peptido sugar-copolymer having the structure of formula (I) as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of the same. There is provided a process to make the β-peptido sugar-copolymer as defined herein. There are further provided medical applications of the β-peptido sugar-copolymer as defined herein. In a preferred embodiment, a block-like copolymer poly(amido-D-glucose)-block-poly-β-(L)-homolysine (PDGu-b-PBLK) synthesized via anionic ring-opening polymerization (ROP) demonstrates an antimicrobial efficacy, an enhanced selectivity towards different bacteria, biocompatibility vs. mammalian cells and spontaneous assembly.

Disclosed herein are compounds in the form of polymers, oligomers and defined molecules having repeating units that all incorporate repeating units formed from an imidazolium group and a biodegradable chain connected to an adjacent repeating unit. The compounds disclosed herein may have antimicrobial activity and so may be used to treat microbial infection and/or to treat surfaces to prevent microbial infections. Also disclosed herein are methods of forming the compounds.